Hydroxycarbamide tablets

DRUG2 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Moderate and High Risk MyelofibrosisMyelofibrosis

Phase 2

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Active, not recruitingNCT05020652

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Moderate and High Risk Myelofibrosis

Start: 2021-11-11End: 2026-02-28Updated: 2025-12-17

Phase 3

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

CompletedNCT04617028

Suzhou Zelgen Biopharmaceuticals Co.,LtdMyelofibrosis

Start: 2021-02-05End: 2023-10-18Updated: 2023-11-13

Related Papers

Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study

Blood2025-11-03

An exploratory analysis of myelofibrosis (MF) patient subgroups by baseline hemoglobin levels in the gecacitinib phase 3 trial.

Journal of Clinical Oncology2025-05-28

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Mielofibrose

Epidemiologia e Serviços de Saúde2025-01-01

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.

2024-12-18

Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study

Blood2024-11-051 citations

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

Blood2024-11-051 citations

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Blood2023-11-026 citations

A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).

Journal of Clinical Oncology2023-06-016 citations